Cardiff Oncology (CRDF) News Today → The World’s Richest Man Blindsided by AI (From Banyan Hill Publishing) (Ad) Free CRDF Stock Alerts $3.58 +0.10 (+2.87%) (As of 03:21 PM ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 13 at 4:05 PM | globenewswire.comCardiff Oncology to Present at Upcoming Investor Conferences in MayMay 10, 2024 | americanbankingnews.comFY2024 EPS Estimates for Cardiff Oncology, Inc. Lifted by Analyst (NASDAQ:CRDF)May 9, 2024 | marketbeat.comHC Wainwright Analysts Raise Earnings Estimates for Cardiff Oncology, Inc. (NASDAQ:CRDF)Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Equities research analysts at HC Wainwright upped their FY2024 earnings per share estimates for Cardiff Oncology in a report released on Monday, May 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings perMay 8, 2024 | americanbankingnews.comCardiff Oncology (NASDAQ:CRDF) Rating Reiterated by HC WainwrightMay 6, 2024 | marketbeat.comCardiff Oncology (NASDAQ:CRDF) Receives "Buy" Rating from HC WainwrightHC Wainwright reissued a "buy" rating and issued a $14.00 target price on shares of Cardiff Oncology in a research note on Monday.May 6, 2024 | americanbankingnews.comCritical Comparison: Cardiff Oncology (NASDAQ:CRDF) and Finch Therapeutics Group (NASDAQ:FNCH)May 4, 2024 | finance.yahoo.comCardiff Oncology First Quarter 2024 Earnings: Beats ExpectationsMay 3, 2024 | msn.comCardiff Oncology, Inc. (NASDAQ:CRDF) Q1 2023 Earnings Call TranscriptMay 3, 2024 | finance.yahoo.comCardiff Oncology Inc (CRDF) (Q1 2024) Earnings Call Transcript Highlights: Strategic Insights ...May 2, 2024 | investorplace.comCRDF Stock Earnings: Cardiff Oncology Beats EPS, Beats Revenue for Q1 2024May 2, 2024 | globenewswire.comCardiff Oncology Reports First Quarter 2024 Results and Provides Business UpdateMay 1, 2024 | marketbeat.comCardiff Oncology (CRDF) Set to Announce Earnings on ThursdayCardiff Oncology (NASDAQ:CRDF) will be releasing earnings after the market closes on Thursday, May 2, Zacks reports.April 25, 2024 | globenewswire.comCardiff Oncology to Report First Quarter 2024 Results and Provide Business UpdateApril 12, 2024 | marketbeat.comCardiff Oncology, Inc. (NASDAQ:CRDF) Forecasted to Earn Q1 2025 Earnings of ($0.28) Per ShareCardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - Analysts at William Blair issued their Q1 2025 EPS estimates for Cardiff Oncology in a note issued to investors on Tuesday, April 9th. William Blair analyst A. Hsieh anticipates that the company will earn ($0.28) per share for the quarter. TheApril 9, 2024 | investorplace.comElection Year Encore: Can 2020's Top 7 Stock Winners Repeat Their Performance in 2024?April 8, 2024 | globenewswire.comCardiff Oncology Presents Novel Preclinical Data at AACR Annual Meeting 2024 that Supports Ongoing First-line RAS-mutated mCRC Clinical StudyMarch 28, 2024 | marketbeat.comCardiff Oncology, Inc. (NASDAQ:CRDF) Short Interest UpdateCardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) saw a significant growth in short interest in March. As of March 15th, there was short interest totalling 2,810,000 shares, a growth of 144.3% from the February 29th total of 1,150,000 shares. Based on an average daily trading volume, of 1,540,000 shares, the days-to-cover ratio is currently 1.8 days.March 27, 2024 | msn.combluebird bio falls as accounting errors force restatementsMarch 21, 2024 | investorplace.comFinding the Next Big Winners: 3 Stocks You Can Snag for Under $5March 16, 2024 | finance.yahoo.comREGN Mar 2024 982.500 callMarch 16, 2024 | finance.yahoo.comREGN Mar 2024 1010.000 putMarch 15, 2024 | finance.yahoo.comCRDF Apr 2024 2.500 callMarch 15, 2024 | finance.yahoo.comCRDF Nov 2024 10.000 putMarch 15, 2024 | finance.yahoo.comCRDF Apr 2024 5.000 callMarch 14, 2024 | finance.yahoo.comREGN Mar 2024 992.500 callMarch 8, 2024 | seekingalpha.comCardiff Oncology: Why The Bulls Are Winning Right Now (Rating Upgrade)March 8, 2024 | marketbeat.comHC Wainwright Weighs in on Cardiff Oncology, Inc.'s Q1 2024 Earnings (NASDAQ:CRDF)Cardiff Oncology, Inc. (NASDAQ:CRDF - Free Report) - HC Wainwright boosted their Q1 2024 earnings per share (EPS) estimates for Cardiff Oncology in a research note issued on Wednesday, March 6th. HC Wainwright analyst R. Selvaraju now anticipates that the company will earn ($0.23) per share for tMarch 6, 2024 | globenewswire.comCardiff Oncology Announces Upcoming Presentations at the AACR Annual Meeting 2024March 4, 2024 | marketbeat.comShort Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Drops By 7.8%Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the recipient of a significant drop in short interest in the month of February. As of February 15th, there was short interest totalling 1,190,000 shares, a drop of 7.8% from the January 31st total of 1,290,000 shares. Based on an average daily volume of 156,900 shares, the days-to-cover ratio is currently 7.6 days.March 3, 2024 | finance.yahoo.comCardiff Oncology Full Year 2023 Earnings: Beats ExpectationsMarch 2, 2024 | seekingalpha.comCardiff Oncology, Inc. (CRDF) Q4 2023 Earnings Call TranscriptMarch 2, 2024 | finance.yahoo.comCardiff Oncology, Inc. (NASDAQ:CRDF) Q4 2023 Earnings Call TranscriptMarch 1, 2024 | msn.comNasdaq Surges 100 Points; ISM Manufacturing PMI Falls In FebruaryMarch 1, 2024 | msn.comSmall Cap-Cardiff Oncology Outlines Data From Discontinued Colorectal Cancer Trial, Stock SoarsMarch 1, 2024 | finance.yahoo.comCardiff Oncology Inc (CRDF) Reports Q4 and Full Year 2023 Financial ResultsMarch 1, 2024 | marketbeat.comPiper Sandler Increases Cardiff Oncology (NASDAQ:CRDF) Price Target to $7.00Piper Sandler lifted their target price on Cardiff Oncology from $5.00 to $7.00 and gave the stock an "overweight" rating in a research report on Friday.March 1, 2024 | uk.finance.yahoo.comQ4 2023 Cardiff Oncology Inc Earnings CallMarch 1, 2024 | finanznachrichten.deCardiff Oncology, Inc.: Cardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRCMarch 1, 2024 | markets.businessinsider.comTD Cowen Sticks to Their Buy Rating for Cardiff Oncology (CRDF)February 29, 2024 | globenewswire.comCardiff Oncology Reports Fourth Quarter and Full Year 2023 Results and Provides Business UpdateFebruary 29, 2024 | globenewswire.comCardiff Oncology Provides Clinical Update on Phase 2 Randomized Second-line ONSEMBLE Trial in Patients with RAS-mutated mCRCFebruary 29, 2024 | globenewswire.comCardiff Oncology Announces First Patient Dosed in Randomized First-line RAS-mutated Metastatic Colorectal Cancer Trial (CRDF-004)February 28, 2024 | benzinga.comCardiff Oncology Earnings PreviewFebruary 26, 2024 | finance.yahoo.comCardiff Oncology to Present at the Cowen 44th Annual Health Care ConferenceFebruary 26, 2024 | globenewswire.comCardiff Oncology to Present at the Cowen 44th Annual Health Care ConferenceFebruary 23, 2024 | marketbeat.comCardiff Oncology (CRDF) to Release Quarterly Earnings on ThursdayCardiff Oncology (NASDAQ:CRDF) will be releasing earnings after the market closes on Thursday, February 29, Zacks reports.February 22, 2024 | finance.yahoo.comCardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business UpdateFebruary 22, 2024 | globenewswire.comCardiff Oncology to Report Fourth Quarter and Full Year 2023 Results and Provide Business UpdateFebruary 18, 2024 | finance.yahoo.comCRDF Mar 2024 2.500 callJanuary 29, 2024 | marketbeat.comShort Interest in Cardiff Oncology, Inc. (NASDAQ:CRDF) Drops By 13.6%Cardiff Oncology, Inc. (NASDAQ:CRDF - Get Free Report) was the recipient of a significant decline in short interest in January. As of January 15th, there was short interest totalling 1,140,000 shares, a decline of 13.6% from the December 31st total of 1,320,000 shares. Based on an average trading volume of 175,600 shares, the short-interest ratio is currently 6.5 days. Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address How to Make 100X on the AI Boom (Ad)For over four decades, Louis Navellier has found the very best tech stocks... Before the rest of the market. Click for his six specific AI stock in the crosshairs CRDF Media Mentions By Week CRDF Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CRDF News Sentiment▼0.710.57▲Average Medical News Sentiment CRDF News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CRDF Articles This Week▼101▲CRDF Articles Average Week Get Cardiff Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDF and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: BCAB News Today SCLX News Today CRDL News Today MOLN News Today VXRT News Today DBVT News Today CLLS News Today GNFT News Today VIGL News Today OMGA News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CRDF) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperInvest Now: Starpax's Cancer Breakthrough Achieving What Others Haven't for a CenturyStarpaxHUGE BUY ALERT: Move Fast, Musk...Stansberry ResearchDemocrats Push to Replace Dollar With Digital Coin, Control Currency.Monetary GoldTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial Metals Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiff Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
